Items where contributor is "Zippelius, Alfred"

2014

Tse, B. W. and Collins, A. and Oehler, M. K. and Zippelius, A. and Heinzelmann-Schwarz, V. A.. (2014) Antibody-based immunotherapy for ovarian cancer: where are we at? Annals of Oncology, Vol. 25, H. 2. pp. 322-331.

2010

Burckhart, Tanja and Thiel, Markus and Nishikawa, Hiroyoshi and Wüest, Thomas and Müller, Dafne and Zippelius, Alfred and Ritter, Gerd and Old, Lloyd and Shiku, Hiroshi and Renner, Christoph. (2010) Tumor-specific crosslinking of GITR as costimulation for immunotherapy. Journal of immunotherapy, Vol. 33, H. 9. pp. 925-934.

Speiser, Daniel E. and Schwarz, Katrin and Baumgaertner, Petra and Manolova, Vania and Devevre, Estelle and Sterry, Wolfram and Walden, Peter and Zippelius, Alfred and Conzett, Katrin Baumann and Senti, Gabriela and Voelter, Verena and Cerottini, Jean-Philippe and Guggisberg, David and Willers, Jörg and Geldhof, Christine and Romero, Pedro and Kündig, Thomas and Knuth, Alexander and Dummer, Reinhard and Trefzer, Uwe and Bachmann, Martin F.. (2010) Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of immunotherapy, Vol. 33, H. 8. pp. 848-858.

2009

Knights, Ashley J. and Nuber, Natko and Thomson, Christopher W. and de la Rosa, Olga and Jäger, Elke and Tiercy, Jean-Marie and van den Broek, Maries and Pascolo, Steve and Knuth, Alexander and Zippelius, Alfred. (2009) Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer immunology, immunotherapy, Vol. 58. pp. 325-338.

2008

Tinguely, M. and Jenni, B. and Knights, A. and Lopes, B. and Korol, D. and Rousson, V. and Curioni Fontecedro, A. and Cogliatti, S. B. and Bittermann, A. G. and Schmid, U. and Dommann-Scherrer, C. and Maurer, R. and Renner, C. and Probst-Hensch, N. M. and Moch, H. and Knuth, A. and Zippelius, A.. (2008) MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer science, Vol. 99, H. 4. pp. 720-725.

Curioni-Fontecedro, A. and Knights, A. J. and Tinguely, M. and Nuber, N. and Schneider, C. and Thomson, C. W. and von Boehmer, L. and Bossart, W. and Pahlich, S. and Gehring, H. and Moch, H. and Renner, C. and Knuth, A. and Zippelius, A.. (2008) MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, Vol. 22, no. 8. pp. 1646-1648.